SYRS News and Press, Syros Pharmaceuticals Inc. From 05/29/20

Highly Selective and Potent Oral CDK7 Inhibitor Shows Robust Anti-Tumor Activity in Colorectal Cancer Models Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data for SY-5609, its highly...

CAMBRIDGE, Mass. , May 28, 2020 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Par...

Investing in companies with superior growth rates can produce outstanding returns over the long term. A stock is essentially a share in the ownership of a business, and the price of the stock will follow the value of the business over time. When the business is growing rapidly and ideally ac...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on the anti-tumor activity of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor,...

Syros Pharmaceuticals, Inc. (SYRS) Q1 2020 Earnings Conference Call May 07, 2020, 08:30 ET Company Participants Naomi Aoki - VP, Corporate Communications & IR Nancy Simonian - President, CEO & Director Joseph Ferra - CFO David Roth - Chief Medical Officer Conference ...

Image source: The Motley Fool. Syros Pharmaceuticals, Inc.   (NASDAQ: SYRS) Q1 2020 Earnings Call May 07, 2020 , 8:30 a.m. ET Operator Continue reading

The following slide deck was published by Syros Pharmaceuticals, Inc. in conjunction with their 2020 Q1 earnings Read more ...

Syros Pharmaceuticals (NASDAQ: SYRS ): Q1 GAAP EPS of -$0.39 beats by $0.03 . More news on: Syros Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Completed Enrollment in Phase 2 Trial Cohort Evaluating SY-1425 in RARA-Positive Relapsed or Refractory AML Patients On Track for 2020 Milestones, Including Clinical Data Readouts for SY-1425 and SY-5609 Well-Funded with Cash Runway into 2022 Management to Host Conference Ca...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, May 7, 2020 to report its first quarter 2020 financial results and provide a co...